Biotechnology - Licensing, Anti-Arthritics/Rheumatics


Popular Filters

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal


US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia


World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…


SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Baxter and Coherus in up to $246 million deal for biosimilar etanercept


US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China


US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Neovacs moving forward in rheumatoid arthritis, say analysts


French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…


Unigene and Nordic Bioscience amend JDV accord; Amgen Vectibix China deal


USA-based Unigene Laboratories (PINK: UGNE) has entered into an equity transfer and exclusive license…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDiabetesLicensingMergers & AcquisitionsNordic BioscienceOncologyPharmaceuticalUGP302Unigene LabsVectibixZhejiang Beta Pharma

Concert Pharma in $300 million-plus deal with Celgene


Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA


US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

AstraZeneca collaborates with Amgen on five MAbs


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs


Belgian drug developer Galapagos (Euronext: GLPG) saw its shares rocket 27% to a record high 13.89 euros…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGalapagosLicensingPharmaceutical

Nektar sells Cimzia and Mircera royalty rights for $124 million


US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties…

Anti-Arthritics/RheumaticsBiotechnologyLicensingNephrology and Hepatology

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Abbott in further deal with Reata


US health care major Abbott Laboratories (NYSE: ABT) has entered into a second mega-million dollar licensing…

Abbott LaboratoriesAnti-Arthritics/RheumaticsbardoxoloneBiotechnologyLicensingNeurologicalPharmaceuticalReata Pharmaceuticals

Biogen Idec in up to $553 million deal with Portola for oral Syk inhibitor program


USA-based Biogen Idec (Nasdaq: BIIB) and Portola Pharmaceutical have entered into an exclusive, worldwide…

Anti-Arthritics/RheumaticsBiogen IdecBiotechnologyLicensingPharmaceuticalPortola PharmaceuticalsRare diseasesResearch

Back to top